The immunosuppressive effect of human cytomegalovirus infection in recipients of allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 36, Issue 6, 2005, Pages 503-509

  Giebel, S ^a,b   Maccario, R ^a   Lilleri, D ^a   Zecca, M ^a   Avanzini, M A ^a   Marconi, M ^a   Di Cesare Merlone, A ^a   Campanini, G ^a   Montagna, D ^a   Travaglino, P ^a   Gentile, R ^a   Telli, S ^a   Pagliara, D ^a   Holowiecki, J ^b   Locatelli, F ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

AlloHSCT; HCMV; T cells

Indexed keywords

CELL SURFACE MARKER; CYCLOSPORIN A; GANCICLOVIR; METHOTREXATE; MITOGENIC AGENT; STEROID; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL ACTIVITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; FEMALE; FREQUENCY ANALYSIS; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INFANT; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE;

ADOLESCENT; ADULT; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; INFANT; LYMPHOCYTE ACTIVATION; MALE; MITOGENS; PREMEDICATION; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 31044454298     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705094     Document Type: Article

References (26)

1. Gerna G, Baldanti F, Grossi P et al. Diagnosis and monitoring of human infection in transplant recipients. Rev Med Microbiol 2001; 12: 155-175.
2. Holowiecki J, Kopera M, Gaciong Z et al. Consensus concerning diagnostics, prophylaxis and treatment of HCMV infection in immunocompromised patients. Acta Haematol Pol 1998; 29: 281-290.
3. Ahn A, Angula A, Chazal P et al. Human cytomegalovirus inhibits antigen presentation by a sequential mutistep process. Proc Natl Acad Sci USA 1996; 93: 10990-10995.
4. Slobedman B, Mocarski ES, Arvin AM et al. Latent cytomegalovirus down-regulates major histocomatibility complex class II expression on myeloid progenitors. Blood 2002; 100: 2867-2873.
5. Reyburn HT, Mandelboim O, Vales-Gomez M et al. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997; 386: 514-517.
6. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci USA 1994; 91: 11879-11883.
7. Carney WP, Iacoviello V, Hirsch MS. Functional properties of T lymphocytes and their substets in cytomegalovirus mononucleosis. J Immunol 1983; 134: 390-393.
8. Kapasi K, Rice GP. Cytomegalovirus infection of peripheral blood mononuclear cells; effects on interleukin-1 and -2 production and responsiveness. J Virol 1988; 62: 3603-3607.
9. Kotenko SV, Saccani S, Izotova LS et al. Human cytomegalovirus harbors its own unique IL-10 homolog (HCMVIL-10). Proc Natl Acad Sci USA 2000; 97: 1695-1700.
10. Jones BC, Logsdon NJ, Josephson K et al. Crystal structure of human cytomegalovirus IL-10 bound to soluble human IL-10R. Proc Natl Acad Sci USA 2002; 99: 9404-9409.
11. Spencer JV, Lockridge KM, Barry PA et al. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J Virol 2002; 76: 1285-1292.
12. Paulin T, Rindgen O, Lomiquist B. Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. Transplantation 1985; 39: 377-384.
13. Gerna G, Baldanti F, Lilleri D et al. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplantation receipients. J Clin Microbiol 2000; 38: 1845-1853.
14. Locatelli F, Percivalle E, Comoli P et al. Human cytomegalovirus (HHCMV) infection in paediatric patients given allogeneic bone marrow transplantation: Role of early treatment of antigenaemia on patients' outcome. Br J Haematol 1994; 88: 64-71.
15. Salvaneschi L, Perotti C, Zecca M et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion 2001; 41: 1299-1305.
16. Ljungman P, Griffiths P, Paya C. Definition of HCMV infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
17. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 1232-1237.
18. Gerna G, Percivalle E, Torsellini M, Revello MG. Standarization of human cytomegalovirus antigenemia assay by means of in vitro-generated pp65-positive peripheral blood polimorphonuclear leukocytes. J Clin Microbiol 1998; 36: 3585-3589.
19. Moretta A, Maccario R, Fagioli F et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol 2001; 29: 371-379.
20. Ljungman P, Reusser P, de la Camara R et al. Management of HCMV infections: Recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004; 33: 1075-1081.
21. Gerna G, Lilleri D, Baldanti F et al. Human cytomegalovirus immediate-early mRNAemia vs pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: A prospective, randomized, open-label trial. Blood 2003; 101: 5053-5060.
22. Roux E, Helg C, Dumont-Girard F et al. Analysis of T-cell repopulation after bone marrow transplantation: Significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984-3992.
23. Montagna D, Locatelli F, Moretta A et al. T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood 2004; 103: 4322-4329.
24. Sing GK, Garnett HM. The effects of human cytomegalovirus challenge in vitro on subpopulations of T cells from seronegative donors. J Med Virol 1984; 14: 363-371.
25. Marr KA, Carter RA, Boeckh M et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366.
26. Grow W, Moreb J, Roque D et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15-19.